- HK$7.41bn
- HK$9.91bn
- HK$4.17bn
Brief: SSY Group Obtains NMPA Approval For Nimodipine Oral Solution
Brief: SSY Group Appoints Wu Heng Yao As Executive Director
Brief: SSY Group Says Ziprasidone Mesilate Receives Registration Approval In China
Hong Kong's SSY Group H1 profit rises on infusion solutions growth
Brief: SSY Group H1 Revenue HKD2,075 Million
Brief: Ssy Group Obtains China Approval For Ozagrel Sodium Injection
Brief: SSY Group Obtains China Drug Production And Registration Approvals For Four Products
Brief: SSY Group Says Gadobutrol Approved As Bulk Drug By China's NMPA
Brief: SSY Gets Approval For Production, Registration Of Choline Fenofibrate Sustained-Release Capsules
Brief: SSY Group Says Baloxavir Marboxil Obtains Registration Approval In China From NMPA As Bulk Drug
Brief: SSY Group Obtains NMPA Approval For Propylthiouracil Tablets (50Mg)
Brief: SSY Group Obtains NMPA Approval For Methocarbamol Tablets (0.5G)
Brief: SSY Group Obtains NMPA Approval For Safinamide Mesylate Tablets
Brief: Ssy Group Obtains Nmpa China Approval For Cefpodoxime Proxetil For Suspension (50Mg)
Brief: Ssy Group Says Letter Of Intent In Relation To License Of Class 1 Innovative Drug Opt101
Brief: SSY Group Obtains NMPA Approval To Become Market Authorization Holder Of Ceftizoxime Sodium For Injection
Brief: Ssy Group Subsidiary Enters Loi For Two Class 2 Modified New Drugs
Brief: SSY Group Says Safinamide Mesylate Obtains First Bulk Drug Approval In China
Brief: SSY Group Obtains China's NMPA Approval For Emedastine Difumarate Eye Drops 0.05% Type 4, Others